CoChat

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS: Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials. Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331). RESULTS: Dose-proportional exposure of liraglutide up to and including 3.0 mg was confirmed. Body weight and sex influenced exposure of liraglutide 3.0 mg, while age ≥70 years, race, ethnicity and baseline glycaemic status did not. Compared with a reference subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body weight. Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc analysis). CONCLUSION: Population pharmacokinetics of liraglutide up to and including 3.0 mg daily in overweight and obese adults demonstrated dose-proportional exposure, and limited effect of covariates other than sex and body weight. These findings were similar to those previously observed with liraglutide up to 1.8 mg in subjects with type 2 diabetes mellitus. Further analysis of exposure-response relationship and its effect on dose requirements is addressed in a separate publication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-016-0410-7

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Model-derived relationship between liraglutide AUC and dose in obese individuals. Data shown are from the phase II dose-finding trial (Trial 3; Astrup et al. [27]) and represent means and 95 % CI. AUC area under the curve, CI confidence interval, N number of subjects
Fig. 1 Model-derived relationship between liraglutide AUC and dose in obese individuals. Data shown are from the phase II dose-finding trial (Trial 3; Astrup et al. [27]) and represent means and 95 % CI. AUC area under the curve, CI confidence interval, N number of subjectsCC BY-NC · PubMed Central
Fig. 2 Influence of covariates on exposure expressed as change in relative steady-state dose-normalised liraglutide exposure (AUC24/dose). Reference subject profile: female, below 70 years of age, 100 kg body weight, White, non-Hispanic or -Latino, without diabetes or prediabetes, dosed by liraglutide 3.0 mg once daily. The parameter ‘body weight’ shows the highest and lowest in the dataset. Mild and moderate/severe renal impairment were defined as ≥60 and <90 ml min−1 and ≥30 and <60 ml min−1, respectively, and ‘no renal impairment’ was defined as ≥90 ml/min. Dotted lines indicate the interval used for bioequivalence testing, for comparison. The column to the right shows geometric mean relative exposures with 90 % CI obtained by likelihood profiling. Covariates above the solid horizontal line were prespecified, and parameters below the solid line were analyzed post hoc. CI confidence interval, AUC area under the curve
Fig. 2 Influence of covariates on exposure expressed as change in relative steady-state dose-normalised liraglutide exposure (AUC24/dose). Reference subject profile: female, below 70 years of age, 100 kg body weight, White, non-Hispanic or -Latino, without diabetes or prediabetes, dosed by liraglutide 3.0 mg once daily. The parameter ‘body weight’ shows the highest and lowest in the dataset. Mild and moderate/severe renal impairment were defined as ≥60 and <90 ml min−1 and ≥30 and <60 ml min−1, respectively, and ‘no renal impairment’ was defined as ≥90 ml/min. Dotted lines indicate the interval used for bioequivalence testing, for comparison. The column to the right shows geometric mean relative exposures with 90 % CI obtained by likelihood profiling. Covariates above the solid horizontal line were prespecified, and parameters below the solid line were analyzed post hoc. CI confidence interval, AUC area under the curveCC BY-NC · PubMed Central
Fig. 3 Liraglutide exposure versus body weight stratified by a sex and b glycaemic status. Data are dose-normalised mean AUC values with 95 % CI for quantiles of baseline body weight (large symbols) and individual exposure estimates (small symbols). Lines are model-based relationships adjusted for other covariate effects. AUC area under the curve, CI confidence interval
Fig. 3 Liraglutide exposure versus body weight stratified by a sex and b glycaemic status. Data are dose-normalised mean AUC values with 95 % CI for quantiles of baseline body weight (large symbols) and individual exposure estimates (small symbols). Lines are model-based relationships adjusted for other covariate effects. AUC area under the curve, CI confidence intervalCC BY-NC · PubMed Central
Fig. 4 Exposure distribution (patient frequency) predicted for liraglutide 3.0 mg in overweight/obese subjects with (Trial 2 [6]) and without T2DM (Trial 1 [5]) compared with liraglutide 1.8 mg in subjects with T2DM [26]. AUC area under the curve, T2DM type 2 diabetes mellitus
Fig. 4 Exposure distribution (patient frequency) predicted for liraglutide 3.0 mg in overweight/obese subjects with (Trial 2 [6]) and without T2DM (Trial 1 [5]) compared with liraglutide 1.8 mg in subjects with T2DM [26]. AUC area under the curve, T2DM type 2 diabetes mellitusCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Federación Mexicana de Diabetes A.C. COFEPRIS approved the first treatment for chronic management of obesity in Mexico [press release], Feb 2015. Available at: http://fmdiabetes.org/aprueba-la-cofepris-primer-tratamiento-para-el-manejo-cronico-de-la-obesidad-en-mexico/ . Accessed Nov 2015.

Cited by

See all 64

Metadata

Authors
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B.
Affiliations
Novo Nordisk (Denmark) (DK)
Corresponding author
Overgaard, Rune V.
Venue
Clinical Pharmacokinetics
Published
2016-05-19
Volume
55
Issue
11
Pages
1413-1422
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2398911378
Cited by
64
References
40
Citations by year
2026: 7 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 1 · 2016: 1
FWCI
3.24
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk (DK)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, pharmacokinetics, weight management, obesity, overweight, GLP-1 receptor agonists, dose proportionality, body weight, sex differences, covariates, exposure-response relationship, type 2 diabetes, prediabetes
MeSH terms
Liraglutide, Adolescent, Adult, Age Factors, Aged, Body Weight, Dose-Response Relationship, Drug, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Models, Biological, Obesity, Prediabetic State, Sex Factors, Overweight, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. https://app.cochat.ai/papers/10.1007/s40262-016-0410-7
The paper
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016). Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-016-0410-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.